Onkologie. 2009:3(2):114-119

The use of cytokines in the treatment for metastatic renal carcinoma in the context of biological therapy

MUDr. Šárka Lukešová, Ph.D, doc. MUDr. Otakar Kopecký, CSc
II. interní klinika FN a LF UK v Hradci Králové a Oddělení klinické onkologie Oblastní nemocnice Náchod, a.s

Although malignant renal tumors account for 1–2 % of all malignant tumors, their incidence in the Czech Republic is the highest in the

world. Given the chemo- and radioresistance of malignant tumors, the use of cytokines in the treatment for metastatic renal carcinoma

represented a major advance. The advent of biological therapy has raised the issues of their appropriate further use and their indication

in the right patient at the right time. These issues are dealt with in the present paper.

Keywords: renal carcinoma, IFN-α, IL-2, sorefenib, sunitinib.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukešová Š, Kopecký O. The use of cytokines in the treatment for metastatic renal carcinoma in the context of biological therapy. Onkologie. 2009;3(2):114-119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z. Nežádoucí účinky interferonu alfa. Vnitř. Lék., 1994; 40(2): 127-129.
    2. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 1993; 11: 661-670. Go to original source... Go to PubMed...
    3. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004; Apr 1; 22(7): 1188-1194. Go to original source... Go to PubMed...
    4. Atzpodien J, Kirchner H, Rebmann U at al. Interleukin-2/ interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2006 Aug 21; 95(4): 463-469. Go to original source... Go to PubMed...
    5. Bartoš J. Sorafenib. Lékové profily. Remedia 2008; 18: 273-282.
    6. Beck J, Bajetta E, Escudier B et al. A large open-label, noncomparative, phase III study of the multi-targeted kinase inhibitor Sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer Suppl 2007; 5: 300 Abstract 4506. Data on file, BSP 2007. Go to original source...
    7. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008 May; 53(5): 917-930. Go to original source... Go to PubMed...
    8. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: role of interleukin-2. Cancer 1997; 80: 1198-220. Go to original source...
    9. Bukowski RM, Negrier S, Elson P. Prognostic factors in patiens with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004; 10(18 Pt 2): 6310S-6314S. Go to original source... Go to PubMed...
    10. Caraceni A, Gangeri L, Martini C, et al. Neurotoxicity of interferon alfa in melanoma therapy: results from a randomized controlled trial. Cancer, 1998; 83: 482-489. Go to original source...
    11. Cohen MC, Huberman M, Nesto RW, et al. Recombinant alpha-2 interferon related cardiomyopathy. Amer. J. Med., 1988; 85: 549-551. Go to original source... Go to PubMed...
    12. Costa LJ, Drabkin HA. Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies. The Oncologist 2007; 12: 1404-1415. Go to original source... Go to PubMed...
    13. Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby maligních onkologických onemocnění: Zhoubný novotvar ledviny (C64). 6. vydání. http://www.linkos.cz.
    14. Dalakas MC, Mock V, Hawkins MJ. Fatigue: definitions, mechanisms, and paradigms for study. Semin. Oncol., 1998; 25(suppl. 1): 48-53.
    15. Dean GE, Spears L, Ferrell BR, et al. Fatigue in patients with cancer receiving interferon alpha. Cancer Pract., 1995; 3: 164-172. Go to PubMed...
    16. Dutcher J, Logan T, Gordon M, et al. 5FU + subcutaneous (SC) interleukin-2 (IL2) plus SC Intron (IFN) in metastatic renal cell cancer (RCC) patients (pts). A CWG study. Proc Am Soc Clin Oncol 1996: 272a.
    17. Fisher RI, Rosenberg SA, Sznol M, et al. High dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J Sci Am 1997; 3: S70-72. Go to PubMed...
    18. Fisher RI, Rosenberg SA, Fyfe G. Longterm survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: Suppl 1: S55-S57. Go to PubMed...
    19. Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J. Clin. Oncol., 1999; 17: 529-533. Go to original source... Go to PubMed...
    20. Fyfe G, Fisher RI, Rosenberg SA, Snzol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma whoreceived high-dose recombinant interlukin-2 therapy. J Clin Oncol 1995; 13: 688-696. Go to original source... Go to PubMed...
    21. Gallagher DC, Bhatt RS, Parikh SM, et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 2007; 13: 2115-2120. Go to original source... Go to PubMed...
    22. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008; 111(12): 5610-5620. Go to original source... Go to PubMed...
    23. Chiarion-Sileni V, Del Bianco P, Romanini A, et al. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI-Mel.A.), BMC Cancer, 2006; 6: 44. Go to original source... Go to PubMed...
    24. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 2001; 6: 34-55. Go to original source... Go to PubMed...
    25. Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin. Oncol., 1998; 25(suppl. 1): 54-63.
    26. Klener P. Nádory ledvin. In: Klinická onkologie. Galén, 2002; 66-71.
    27. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824-832. Go to original source...
    28. Lukešová Š, Kopecký O, Dvořák J, et al. Interferon alfa v léčbě metastazujícího renálního karcinomu. Interní Medicína pro praxi, 2006; 10: 432-438.
    29. Masarykův onkologický ústav v Brně, Národní onkologický registr. Epidemiologie zhoubných nádorů v České republice. http://www.svod.cz.
    30. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. Go to original source... Go to PubMed...
    31. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999 Jan 2; 353(9146): 14-17. Go to original source...
    32. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification od 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2530-2540. Go to original source... Go to PubMed...
    33. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980. Go to original source... Go to PubMed...
    34. Nair S, Ernstoff M, Bahnson R, et al. Interferon induced reversible acute renal failure with nephrotic syndrome. Urology, 1992; 39(2): 169-172. Go to original source... Go to PubMed...
    35. Negrier S. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J Clin Oncol 2004; 22: 1174-1176. Go to original source... Go to PubMed...
    36. Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program. Ann Oncol 2006; 17: ix32-33.
    37. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272-1278. Go to original source... Go to PubMed...
    38. Negrier S, Gomez F, Douillard JY, et al. Prognostic factors of response or silure of treatment in patiens with metastatic renal carcinomas treated by cytokines: a report from Groupe Francais dÍmunotherapie. World J Urol 2005; 23: 161-165. Go to original source... Go to PubMed...
    39. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol, 2005; ASCO 23: 16S, Part I of II (June 1 Supplement): 4511. Go to original source...
    40. Negrier S, Jäger E, Porta C, et al. Sorafenib in patients with advanced renal cell carcinoma and prior cytokine therapy: subgroup analysis of targets. Annals of Oncology 17 (Supplement 9): ix144-ix157, 2006. Abstract 4390.
    41. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. Go to original source... Go to PubMed...
    42. Petruželka L. Nové možnosti systémové léčby karcinomu ledviny. Remedia 2008; 1:35-46.
    43. Samlowski WE, Vogelzang NJ. Emerging drugs for the treatment of metastatic renal cancer. Expert Opin Emerg Drugs 2007; 12: 605-618. Go to original source... Go to PubMed...
    44. Scalzo S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur. J. Cancer, 1990; 26: 1152-1156. Go to original source... Go to PubMed...
    45. Selby P, Kohn J, Raymond J, et al. Nephrotic syndrome during treatment with interferon. Brit. Med. J., 1985; 290: 1180. Go to original source... Go to PubMed...
    46. Signoretti S, Regan M, Atkins M. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int. 2008 Jun; 101 Suppl 4: 31-35. Go to original source... Go to PubMed...
    47. SPC PROLEUKIN. Novartis 2007.
    48. SPC Roferon-A. Roche 2007.
    49. Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol. 2008 Jun; 179(6): 2096-2102. Go to original source... Go to PubMed...
    50. Upton MP, Parker A, Youmans A, et al. Histologic predictors od renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28: 488-495. Go to original source... Go to PubMed...
    51. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon alfa therapy. Semin. Oncol., 1998; 25(suppl. 1): 39-47.
    52. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132. Go to original source... Go to PubMed...
    53. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 1997; 3(Suppl 1): S79-84. Go to PubMed...
    54. Zachoval R, Urban M, Heráček J, et al. Současný pohled na metastazující karcinom ledviny z hlediska přežití v závislosti na druhu terapie. Urologie pro praxi 2003; 5: 190-192.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.